The role of ␤-adrenergic receptors (␤-ARs) remains controversial in normal and tumor breast. Herein we explore the cAMP signaling involved in ␤-AR-dependent control of proliferation and adhesion of nontumor human breast cell line MCF-10A. Low concentrations of a ␤-agonist, isoproterenol (ISO), promote cell adhesion (87.5% cells remaining adherent to the plastic dishes following specific detachment vs. 
␤-Adrenergic receptors (␤-ARs) are prototypical G-protein-coupled receptors (GPCRs) activated by catecholamines and encompass 3 different subtypes, ␤ 1 -, ␤ 2 -and ␤ 3 -AR, each of which associates with specific physiological actions (1) . These receptors preferentially couple to the heterotrimeric G s protein activating adenylyl cyclase and producing a transient intracellular second messenger cAMP flow that propagates the signal through direct activation of 2 major downstream effectors: protein kinase A (PKA) and the guanine nucleotide exchange protein activated by cAMP (Epac) (2) .
Cyclic AMP, either via PKA and/or Epac, controls numerous biological functions, many of which are intimately associated with cancer development, such as stimulation (3) or inhibition (4) of cell proliferation, cell differentiation (5), or migration (6 -8) . Indeed, cAMP/PKA has been shown to participate at the onset and maintenance of adrenal cortex (9) and thyroid neoplasms (10) . cAMP production also induces ovarian cancer progression (11) via a PKA-Src-dependent mechanism (12) . By opposition, cAMP promotes growth inhibition in a broad spectrum of human carcinomas (13) , fibrosarcomas (14) , and leukemia (15) . One of the first cellular functions attributed to Epac was its ability to mediate cell adhesion; this occurs essentially via Rap1 activation, its cognate downstream effector (16 -19) . The signaling mechanisms involved in Epac-induced cell adhesion are a matter of great interest, because of its importance in processes such as inflammation and cancer.
The expression of ␤-ARs, predominantly of the ␤ 2 subtype, has been characterized in several human breast cancer cell lines (20 -23) and breast cancer tissue samples (24, 25) . The data connecting ␤-AR and breast cancer still remain controversial, and little is known about the ␤ 2 -AR-associated signaling pathways in normal and tumor breast. Several authors suggested the use of ␤-AR antagonists as a therapeutic option for breast cancer (26, 27) . However, an increase of cAMP levels following ␤ 2 -AR stimulation has been shown to inhibit the growth of several human breast cancer cells both in vitro and in vivo (21, 23, 28, 29) . We and others have already demonstrated that this inhibition was associated with blockage of the Raf-1/Mek-1/extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) pathway by cAMP-dependent activation of PKA but not of Epac (23, 28) . cAMP also inhibits migration of highly invasive MDA-MB-231 cells (6, 7) and the expression of relevant proteins involved in breast cancer metastasis. These effects are mediated by both PKA-and Epacdependent pathways (30) .
␤-ARs have also been described in the noncancer breast HBL-100 cell line (31) . However, the role of ␤-AR activation in these cells remains largely unknown. Only 1 recent study described that ␤-AR activation leads to cAMP production and subsequent polarization of MCF-10A mammary epithelial cells, thus contributing to lumen formation in 3-dimensional cultures (5) . In this study the prodifferentiation action of ␤-AR most likely argues for an antiproliferative effect; however, the ␤-subtype involved in these effects still remains to be defined.
Taken together, these studies suggest an antiproliferative action of ␤-ARs in human breast cancer cells and tumors. However, the ␤ subtypes and associated signaling pathways involved and their biological function still remain largely unknown in noncancer breast cell lines. In the present study, we explored the endogenous ␤-adrenergic regulation of the proliferative/ adhesive properties of the nontumor human breast cell line MCF-10A. We identified a dosage-dependent signaling in which low isoproterenol (ISO) concentrations target a ␤ 2 -AR population localized in raft microdomains and stimulate a G s /cAMP/Epac/adhesion signaling module while higher concentrations engage a concomitant activation of another ␤ 2 -AR population outside rafts and inhibit proliferation by a G s /cAMP/ PKA-dependent signaling module.
MATERIALS AND METHODS

Drugs and reagents
The cAMP analogs para-chlorophenylthio-2=-O-methyladenosine-3=,5=-cyclic monophosphate (CPT), N6-benzoyladenosine-3=,5=-cyclic monophosphate (Bnz), 8-bromoadenosine-3=,5=-cyclic monophosphate, and its Rp counterpart (Rp-8-BrcAMP) and the Epac-specific inhibitor ESI-09 were purchased from BioLog Life Science Institute (Bremen, Germany). The MEK inhibitor PD98059 (PD) was obtained from Calbiochem (Merck Chemicals, Nottingham, UK). Pertussis toxin from Bordetella pertussis, insulin, epidermal growth factor (EGF), hydrocortisone, (Ϫ)-adrenaline, (Ϫ)-noradrenaline, ISO, salbutamol, dobutamine, ICI-118,551, atenolol, H-89, forskolin, ␤-methyl-cyclodextrin, p-coumaric acid, and all other chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA). UK14304 was kindly provided by Pfizer (Sandwich, UK).
Cell culture and transfection
MCF-10A cells were obtained from American Type Culture Collection (ATCC; Manassas, VA, USA) and routinely grown in HEPES-buffered DMEM/Ham F12 culture medium containing antibiotics (100 g/ml streptomycin, 100 IU/ml penicillin) and supplemented with 10% fetal calf serum (all from Invitrogen, Life Technologies, Rockville, MD. USA), 2 g/ml insulin, 20 ng/ml EGF, and 0.1 M hydrocortisone. Cells were subcultured once weekly by trypsinization (0.25% trypsin, 0.025% EDTA). For bioluminescence resonance energy transfer (BRET) experiments, MCF-10A cells were transiently transfected by electroporation with the indicated vectors (one 20 ms pulse at 1700 V) according to the manufacturer's procedures (Neon Transfection System MPK5000, Invitrogen) or using FuGENE (Promega, Madison, WI, USA). Then 4.5 ϫ 10 5 transfected cells/well were plated onto 6-well plates, and BRET experiments were conducted 48 h post-transfection.
Measurement of cell proliferation
Cells were seeded in 6-well plates (3ϫ10 5 cells/well) for cell counting or 96-well plates (5ϫ10 3 cells/well) for DNA synthesis experiments, grown during 24 h in complete medium and then maintained for 18 h in growth factor/serum-free culture medium. Cell proliferation tests were then conducted in DMEM/Ham F12 medium supplemented with 2% charcoalstripped fetal calf serum, 2 ng/ml EGF, 2 g/ml insulin, and 0.1 M hydrocortisone in the presence or absence of 0.1 M ISO, which was changed every day. Proliferation response was evaluated at the indicated times by automatic cell counting (Beckman Coulter Z1 Cell-Counter, Beckman Coulter, Fullerton, CA, USA) or by methyl [ 3 H]-thymidine incorporation (0.4 Ci/well; DuPont NEN, Boston, MA, USA). After 6 or 24 h, cells were harvested in a Nunc Cell Harvester 8 (Nunc, Roskilde, Denmark), and radioactive nuclei retained into the glass fiber filters were counted in a liquid scintillation counter.
Measurement of Erk1/2 phosphorylation
Cells were seeded in 6-well plates (2.5ϫ10 5 cells/well) and cultured over 24 h in complete medium. Cells were then growth factor/serum starved for 18 h. On the experiment day, cells were pretreated or not for 20 min with the indicated inhibitor and then stimulated or not for 20 min with the different agonists. Cells were then rapidly washed with ice-cold PBS and lysed in RIPA buffer (10 mM Tris, pH 7.5; 150 mM NaCl; 2 mM Na ortho-vanadate; 0.1% SDS; 1% Igepal; and 1% Na deoxycholate). Equal amounts of proteins were separated on 10% SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica, MA, USA). Phosphorylated active Erk1/2 (p-Erk1/2) was detected using anti-pErk1/2 monoclonal antibody 1:1000 (sc-7383, Santa Cruz Biotechnology, Dallas, TX, USA). The membranes were stripped of IgG and reprobed with Erk2 (sc-154, Santa Cruz Biotechnology) or Erk1 (sc-94, Santa Cruz Biotechnology) polyclonal antibodies (1:2000) for protein loading normalization. Membranes were revealed by chemiluminescence using horseradish peroxidase-conjugated secondary antibody to anti-mouse or anti-rabbit IgG 1:10,000 (Amersham Biosciences GE Healthcare, Buc, France) and enhanced chemiluminescence detection solution (1.25 mM luminol, 0.2 mM p-coumaric acid, 0.06% v/v hydrogen peroxide, and 100 mM Tris-HCl, pH 8.8). Immunoblots were exposed to an autoradiographic film (Amersham Hyperfilm, GE Healthcare) and quantified by densitometry with ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA). p-Erk1/2 was normalized according to protein load by expressing the data as a ratio of p-Erk1/2 over total Erk1 or Erk2 as indicated.
Immunofluorescence
Cells were seeded and cultured for 24 h in 6-well plates containing glass coverslips precoated with poly-l-lysine (1 mg/ml, Sigma-Aldrich) and then growth factor/serum starved for 18 h. On the day of the experiment, cells were treated or not for 15 min with the indicated compounds and then incubated during 15 min in Mg 2ϩ /Ca 2ϩ -free PBS. Cells were then washed, fixed with 4% paraformaldehyde in PBS for 10 min, permeabilized 15 min in blocking buffer (PBS, 0.3% Triton X-100, 0.2% BSA), and incubated 1 h at room temperature with anti-mouse ␤1-integrin antibody 1:1,000 (sc-9970, Santa Cruz Biotechnology). Immunoreactivity was revealed using a Texas Red conjugated secondary goat antimouse antibody 1:500 (Invitrogen, Molecular Probes). Cell nuclei were stained with 4=,6-diamidino-2-phenylindole 1:500 (Sigma-Aldrich) for 10 min. Visualization of fluorescence was monitored by an epifluorescence illuminating system, and digital images were captured using the AxioVision LE software (Carl Zeiss, Oberkochen, Germany).
Measurement of cell adhesion
Cells were seeded, in 6-well plates (3ϫ10 5 cells/well) for 48 h and pretreated or not for 20 min with the indicated inhibitors or antagonists and then exposed or not to the different ligands. The medium was removed, and the cells were incubated in Mg 2ϩ /Ca 2ϩ -free PBS containing 0.5 mM EDTA and 0.25% trypsin. After 15 min incubation at room temperature under constant shaking, detached cells were collected and counted (detached cells). Cells that resisted the treatment and remained adherent to the plastic were harvested following an additional 30 min incubation in Mg 2ϩ /Ca 2ϩ -free PBS containing 2.5 mM EDTA and 1.25% trypsin and counted (attached cells) using a cell counter. The percentage of adherent cells was calculated as follows: attached cells ϫ 100/(attached cellsϩdetached cells). This assay was validated by comparison with the method described by Bos et al. (16) and gave similar results.
Bioluminescence resonance energy transfer measurement
Encoding vectors for PKA subunits BRET probes RI␣-Rluc8 and GFP2-C␣ were previously described (32). GFP2-EPAC1-Rluc8 was obtained by subcloning EPAC1 coding sequence in pGFP2-MCS-Rluc8, obtained from Rluc8 subcloning in pGFP2-MCS-Rluc vector (Perkin Elmer, Wellesley, MA, USA). All generated constructs were confirmed by DNA sequencing. BRET constructs were transiently cotransfected into MCF-10A cells as indicated in the figure legends. At 48 h following transfection, cells were washed with PBS, detached with PBS/5 mM EDTA, and resuspended in PBS/0.1% (w/v) glucose at room temperature. Cells were then distributed in a 96-well microplate (Wallac, Perkin Elmer) and incubated in the presence or absence of forskolin and ISO for 30 min. BRET 2 between Rluc8 and GFP10/GFP2 was measured after the addition of the Rluc8 substrate coelenterazine 400a (5 M; Interchim, Montulçon, France). BRET 2 readings were collected using a modified Infinite F500 (Tecan Group, Männedorf, Switzerland). The BRET 2 signal was calculated by the ratio of GFP2 (510 -540 nm) emission over the light emitted by the Rluc8 (370 -450 nm).
Total RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted using RNeasy kit (Qiagen, Courtaboeuf, France). First-strand cDNA was synthesized using the SuperScriptII reverse transcriptase mix (Invitrogen). Negative controls without reverse transcriptase were performed to verify absence of contamination with genomic DNA. The primers used were from Applied Biosystems (Foster City, CA, USA): ADRB1: Hs00265096_s1; ADRB2: Hs00240532_s1 and ADRB3: Hs00609046_m1, 18S: Hs03928990_g1. Fluorogenic probe mix and the TaqMan Universal PCR Master Mix were Applied Biosystems. All amplification reactions were performed in duplicate from 20 ng cDNA using the Mx4000 Multiplex Quantitative PCR System (Stratagene, La Jolla, CA, USA) using the following conditions: 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Results were analyzed with Strategene MX4000 software. The threshold cycle C t method (33) was used to calculate relative gene expression, and results were normalized to the C t value of the housekeeping 18S gene.
Quantification of cAMP cell content
Total cAMP content was quantified using a competitive radio-binding assay for PKA using [ 3 H]-cAMP, as described previously (34) . Briefly cells were seeded in 24-well plates (1.7ϫ10 5 cells/well) in complete medium. After 24 h, medium was removed, and cells were incubated in RPMI medium without phenol red at 37°C for 10 min with different ISO concentrations and in the presence of 1 mM phosphodiesterase inhibitor 3-isobutyl-methylxantine. Stimulations were stopped by ethanol addition, and total cAMP was quantified. Cell extracts were centrifuged for 3 min at 3000 g at 4°C, and the recovered supernatant was evaporated and then resuspended in 50 mM Tris-HCl (pH 7.4) with 0.1% BSA for cAMP quantification.
Evaluation of PKA/Epac BRET probes distribution in light density membrane microdomains
Encoding vectors for PKA subunits BRET probes RI␣-Rluc8 and GFP2-C␣ or Epac1 BRET probe GFP2-EPAC1-Rluc8 were transiently transfected in MCF-10A cells as described for BRET experiments. At 48 h post-transfection, detergentresistant membranes were obtained by sucrose flotation after solubilization of either whole cell. Briefly cells where solubilized in ice-cold lysis buffer (25 mM Tris, pH 7.4; 140 mM NaCl; 2 mM EDTA; and Roche protease inhibitor cocktail containing 1% v/v triton X-100). The resulting preparations were loaded on a sucrose step gradient (5-40% discontinuous sucrose gradient). Sucrose solutions were prepared in the lysis buffer. Gradients were then centrifuged at 200,000 g for 18 h in an SW41 rotor (Beckman Optima L-100 XP Ultracentrifuge; Beckman Coulter). Twelve 1-ml fractions were collected from the top of the gradients. Each fraction was incubated in the presence of 5 M coelenterazine H, and the total luminescence was measured using the Mithras LB 940 instrument (Berthold Technologies, Bad Wildbad, Germany). GM1 gangliosides were detected by dot-blot using peroxidase-coupled cholera toxin subunit B (Invitrogen).
Statistical analysis
Results are expressed as means Ϯ sem of Ն3 independent experiments as indicated. Statistical analysis was carried out using GraphPad Prism 4 software (GraphPad Software, San Diego, CA. USA). Statistical significance of the data was assessed using ANOVA followed by Dunnett's multiple test, Bonferroni or Tukey's test according to the design of the experiment. Unpaired Student's t test was used when comparing 2 groups. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
Femtomolar ␤-agonist concentrations promote MCF-10A cell adhesion
The effect of ISO, a nonselective ␤-agonist, was first tested on MCF-10A cell adhesion. For that purpose, we performed an adhesion assay by quantifying the percentage of cells remaining adherent to the plastic dishes following a specific cell detachment treatment as described in Materials and Methods. Here 0.1 M ISO treatment resulted in a large and significant increase in the proportion of adhesive cells: 87.5 Ϯ 6.3 vs. 35.0 Ϯ 9.3% in control, P Ͻ 0.0001 (Fig. 1A) . The effect of the ␤-agonist on MCF-10A cell adhesion was further reinforced by immunofluorescence labeling of cell-matrix contacts using a ␤1-integrin antibody (Fig. 1B) . Indeed, ISO treatment prevented cells from rounding and cell-matrix contact disruption since ␤1-integrin staining of the cells was markedly increased following detachment procedure when compared to control cells. ISOpromoted adhesion of MCF-10A cells was fast and robust, as the maximum of adhesion was reached almost immediately after 1 min of ISO treatment (82.6Ϯ5.3% of cells remaining adherent vs. 41Ϯ5.3% in control, PϽ0.01; Fig. 1C ). It is noteworthy that, according to the low Hill slope value (0.248), the ISO dose-response curves were significantly better fitted using a 2-phase than a 1-phase model (Fϭ10.66; PϽ0.0001) with an EC 50 of 16.5 Ϯ 11.5 fM for the first phase and an EC 50 of 4.08 Ϯ 3.09 nM for the second phase (Fig. 1D) .
Nanomolar ␤-agonist concentrations inhibit MCF-10A cell proliferation through inhibition of Erk1/2 phosphorylation
The effect of ISO was next assessed on cell proliferation by evaluation of cell growth kinetics. Here 0.1 M ISO resulted in a marked decrease in cell proliferation over time ( Fig. 2A) . The inhibitory action of ISO on MCF-10A growth was significant after 24 h of treatment (16.3Ϯ2.1% reduction vs. control, PϽ0.001) and resulted in a 37.1 Ϯ 3% (PϽ0.001 vs. control) reduction of cell growth after 48 h (Fig. 2A) . These results were confirmed by quantification of DNA synthesis by a [ 3 H]-thymidine incorporation assay, which showed a (Fig. 2B ). This effect remained constant after 24 h ISO exposure (33.2Ϯ2.4% reduction vs. control, PϽ0.001). Given the central role of mitogen-activated protein kinases (MAPKs), and more specifically the Erk1/2 pathway in the regulation of cell proliferation, we examined the contribution of Erk1/2 to the proliferative effect of ISO. [ 3 H]-thymidine incorporation assays were conducted in the presence or not of PD, a specific and soluble MEK1 and 2 (Erk1/2 direct kinase effector) inhibitor. Cells were incubated for 24 h with 50 M PD, a concentration that dramatically inhibited Erk1/2-phosphorylation in these cells (Fig. 2C, inset) . PD significantly decreased (Fig. 2C) . Inhibition of Erk1/2-phosphorylation induced by 0.1 M ISO was significant after 15 min stimulation and remained sustained over time at least until 200 min (PϽ0.01; Fig. 2D ). Moreover, ISO significantly inhibited Erk1/2-phosphorylation according to a 1-site model with an EC 50 of 0.25 Ϯ 0.13 nM (Fig. 2E) . independent experiments, performed in triplicates. Statistical significance was assessed using ANOVA followed by a Bonferroni (A, B) or Dunnett's test (C-E). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. (Fig. 3A) .
␤-AR specificity of the inhibition of MCF-10A proliferation was assessed by measuring Erk1/2 phosphorylation following 20 min stimulation with different adrenergic agonists (Fig. 3B) . Similarly to the inhibitory action of 0.1 M ISO (68.0Ϯ9.0% decrease, PϽ0.01), a significant decrease of the basal Erk1/2-phosphorylation was also observed when cells were exposed to 0.1 M natural catecholamines, epinephrine (Epi; 71.3Ϯ13% reduction vs. control, PϽ0.01), or norepinephrine (NE: 82Ϯ0.9% decrease, PϽ0.01). By contrast, 5 min exposure to 20 ng/ml EGF evoked a significant 98 Ϯ 13% (PϽ0. 50 : 0.31Ϯ0.16 nM; Fig. 3C ), whereas the potency of the predominantly ␤ 1 -AR agonist dobutamine (Dob) in promoting inhibition was weaker (EC 50 : 99.9Ϯ70 nM; Fig. 3C ), thus indicating that the inhibition of Erk1/2-phosphorylation was primarily mediated by ␤ 2 -AR activation. In further support of this conclusion, similar experiments performed with ␤-antagonists showed that ICI-118,551 (ICI), a ␤ 2 -AR selective antagonist, was able to block the Epi-mediated inhibition of Erk1/2-phosphorylation in MCF-10A cells at concentrations as low as 10 nM, while atenolol, a ␤ 1 -selective antagonist, had no effect over a wide range of concentrations (Fig. 3D) .
Similarly, we determined the ␤-AR subtype involved in the stimulation of MCF-10A cell adhesion. Endogenous catecholamines Epi and NE but also ISO (0.1 M) all induced a significant increase in cell adhesion (Epi: 87Ϯ7.5%; NE: 71Ϯ9.7%; ISO 87.7Ϯ6.34% vs. control 35.2Ϯ9.36%, PϽ0.01), while UK did not have any effect on cell adhesion (Fig. 3E ). More selective ␤ 2 -agonists, Salb and clenbuterol, also evoked a significant increase in cell adhesion at 10 nM, while 10 nM Dob failed to induce cell adhesion. Moreover, only the ␤ 2 -specific antagonist ICI was able to dose dependently inhibit the Epi-induced cell adhesion (Fig. 3F) , thus demonstrating that adrenergic activation of MCF-10A cell adhesion is also controlled by the ␤ 2 -AR subtype.
␤ 2 -AR regulates MCF-10A cell proliferation and adhesion through two distinct cAMP pathways ␤ 2 -AR dually couples to both G s and G i proteins to regulate adenylyl cyclase (AC), but can also signal via G protein-independent pathways (35) . To investigate the molecular mechanisms whereby ␤ 2 -AR decreases proliferation but increases adhesion of MCF-10A cells, we first assessed the implication of the G-protein/cAMP pathway. Interestingly, stimulation with 10 M forskolin induced a significant reduction of basal Erk1/2-phosphorylation (Fig. 4A) while significantly promoting cell adhesion comparable to that observed in the presence of ISO (Fig. 4B) . Similar results were obtained when cells were stimulated with 100 M 8-Br-cAMP (8-Br), a permeable analog of the natural cAMP (Fig.  4A, B) . Pretreatment with 100 ng/ml pertussis toxin (PTX) for 16 h did not modify either Erk1/2-phosphorylation inhibition or adhesion activation mediated by ␤ 2 -AR activation (Fig. 4C, D) , while it completely prevented the inhibitory effect of UK on forskolin-mediated Erk1/2-phosphorylation inhibition (Fig. 4C, right  panel) , suggesting that the regulation of ␤ 2 -AR-dependent proliferation and adhesion is not a consequence of receptor coupling to G i , but rather depends on the classical activation of a G s AC/cAMP pathway.
To get further insight into the cAMP downstream effectors involved in proliferation inhibition and cell adhesion stimulation, we next assessed the implication of PKA and Epac, the two cAMP direct effectors (2) . For that purpose, we tested pharmacological inhibitors/ activators exhibiting specificity toward PKA or Epac: H-89 is a specific PKA inhibitor; Bnz is a potent general activator of PKA with poor Epac efficacy; Rp-8-Br-cAMP (Rp) is a competitive inhibitor of cAMP binding to PKA discriminating between the two PKA isoforms and exhibiting more PKAI selectivity (36) ; the CPT is a potent stimulator of Epac and an extremely poor PKA activator; ESI-09 is a new inhibitor of both Epac1 and Epac2, displaying 100-fold selectivity for Epac proteins compared to PKA (37) . As shown in Fig. 4E , the inhibition of Erk1/2-phosphorylation mediated by ISO was mimicked by stimulation with 100 M Bnz but not by 100 M CPT, most likely indicating that inhibition of cell proliferation occurred through PKA activation. These results were confirmed by the use of 100 M Rp or 50 M H-89 (Fig. 4E ) which completely prevented ISO-dependent inhibition of Erk1/2 activation, while 50 M ESI-09 had no effect (Fig. 4E) . On the contrary, only CPT and not Bnz was able to mimic ISO-mediated stimulation of cell adhesion (Fig. 4F) , while 50 M ESI-09 (but not H-89 or Rp) pretreatment was highly effective at inhibition of cell adhesion induced by different ISO concentrations (Fig. 4F) , thus strongly supporting that ISO promotes cell adhesion through an Epac-dependent pathway. All these results demonstrating the specific roles of PKA and Epac in cell proliferation and cell adhesion respectively were confirmed by complementary molecular/genetic approaches competing with endogenous PKA or Epac proteins by transiently overexpressing a PKA inhibitor (PKI; ref. 38) or an Epac-dominant negative (NEpac; ref. 39) . Indeed, specific inhibition of PKA by PKI overexpression did not modify ISO-induced cell adhesion but completely prevented ISO-mediated inhibition of Erk1/2 phosphorylation (Supplemental Fig. S1A) . Conversely, overexpression of N-Epac did not affect ISO-mediated p-Erk1/2, while it significantly decreased cell adhesion induced by ISO by 21.1 Ϯ 3.1% (Supplemental Fig. S1B ). Finally, cell adhesion promoted by ISO-dependent cAMP production was completely independent from Erk1/2-phosphorylation, since it was completely insensitive to PD (Fig. 4G) .
Altogether these results demonstrate that ISO triggers both inhibition of Erk1/2-phosphorylation (proliferation) and activation of cell adhesion through stimulation of the same ␤ 2 -AR receptor but using distinct pathways, both dependent on cAMP production. While the inhibition of Erk1/2-phosphorylation depends on PKA activation, conversely, the increase in cell adhesion relies on an Epac-dependent mechanism. Interestingly, while both PKA and Epac are both cAMP effectors, we were unable to depict fentomolar cAMP production promoted by ISO in MCF-10A cells (Fig.  4H ) and contrary to ISO-induced cell adhesion (Fig.  1D) , ISO-cAMP dose-response curves were fitted to a 1-site model with an EC 50 of 200.3 Ϯ 9.6 nM (Fig. 4H) .
␤ 2 -AR regulates cell proliferation and adhesion through two distinct compartmentalized receptor populations
Because ISO was regulating MCF-10A cell proliferation and adhesion through distinct cAMP-dependent pathways, we next evaluated if these effects could rely on activation of different ␤ 2 -AR populations distributed along distinct plasma membrane microdomains. More specifically, we assessed the compartmentalization into cholesterol-enriched raft membrane domains, which classically concentrate specific receptor/effectors and direct specific cellular signaling when compared to nonraft domains (40) . For that purpose we took advantage of the use of the pharmacological ␤-methyl-cyclodextrin (␤CD), a specific scavenger that extracts cholesterol from the plasma membrane, thus downregulating the presence of raft microdomains. A previous report described that pretreatment of MCF-10A cells with 5 mM ␤CD promoted ϳ50% cholesterol depletion in these cells (41) . Pretreatment of MCF-10A cells with different ␤CD concentrations up to 5 mM caused a significant dose-response inhibition of ISOpromoted cell adhesion with no significant modifica-tion of basal cell adhesion (Fig. 5A) . Interestingly, similar ␤CD treatments had no effect on the inhibition of Erk1/2-phosphorylation mediated by ISO (Fig. 5B) . Thus, these results most likely indicate that ISO promotes MCF-10A cell adhesion by activating a ␤ 2 -AR localized into specific raft microdomains, while it inhibits Erk1/2-phosphorylation through activation of another ␤ 2 -AR present in nonraft domains. These conclusions were reinforced by bioluminescence resonance energy transfer (BRET 2 ) experiments to directly assess the activation of PKA and Epac by ␤ 2 -AR in MCF-10A cells. The activation of both PKA and Epac1 BRET biosensors by cAMP is reflected by a decrease in the BRET signal, correlating with PKA regulator subunit dissociation from the catalytic subunit (32) or a conformational change in Epac1. Thus, when MCF-10A cells were transiently transfected with PKAI or Epac1 BRET biosensors, 10 M forskolin stimulation promoted a significant BRET decrease for both biosensors, validating the cAMP-dependent activation of both effectors in these cells (Fig. 5C, D) . Interestingly, PKA biosensor activation only occurred at high ISO concentrations, as indicated by the significant decrease of the BRET signal in the presence of 10 M ISO but not 0.1 nM (Fig. 5C ). In contrast, Epac1 was dose dependently activated at both low and high ISO concentrations (0.1 nM and 10 M), as reflected by the gradual decrease in the BRET signal (Fig. 5D ). Specific ISO responses toward PKA and Epac probes did not relate to specific and different localization of the two probes since they distributed similarly inside and outside cholesterol-enriched domains in sucrose gradients following cell solubilization with 1% Triton-X100 (Supplemental Fig. S2 ). These results corroborate our previous findings and support the idea that low ISO concentrations promote cell adhesion only via Epac activation in lipids rafts, while high ISO concentrations engage another additional cell proliferation inhibition mediated by PKA and not by Epac in non-cholesterol-enriched domains (Fig. 6) .
DISCUSSION
The results presented in this paper unveil important molecular mechanisms through which the ␤ 2 -AR couples with the cAMP signaling machinery as a function of agonist dose. One major finding of our study is that ␤ 2 -AR coordinates both stimulation of adhesion and inhibition of proliferation of nontumor breast MCF-10A cells using a dose-dependent but dual cAMP-based signaling mechanism. Indeed, we found that low ␤-agonist concentrations trigger cell adhesion exclusively through a cAMP/ Epac-dependent pathway, whereas higher concentrations engage an additional cAMP module using PKA as effector and mediating the inhibition of Erk1/2-dependent cell proliferation (Fig. 6 ). This original dosedependent regulation of ␤ 2 -AR signaling has previously been reported for the MAPK Erk1/2 activation in MEF cells, in which a G-protein-dependent and another G Data represent means Ϯ sem of 3-5 independent experiments. Statistical significance was assessed using ANOVA followed by a Tukey's test. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 between stimulated and nonstimulated cells (control);protein-independent, but Src-dependent, mechanism were identified for low and high agonist concentrations, respectively (42) . The researchers speculated that low agonist concentrations favored the engagement of the G protein to the receptor in agreement with high affinity agonist binding, while higher concentrations should lead to activation of a non-G-protein signaling. This hypothesis could not be reconciled with our results, since we showed that both agonist-dependent phases required cAMP production most probably through direct G s activation. Moreover, and similarly to the study of Sun et al. (42) , we found that the signaling pathways involved in the effects of high agonist concentrations resulted from the addition of PKA activation to the Epac activation observed at low concentrations, thus precluding the existence of a dose-dependent switch mechanism as originally suggested. It remains unclear how ␤ 2 -AR can indeed elicits two different signaling outputs when binding a single ligand. In the presence of high agonist concentrations, purified ␤ 2 -AR has been shown to exist in two distinct active biophysical conformations (43) , which could underlie the two different ␤ 2 -AR signaling outputs observed at high and low ISO concentrations. In this regard, an interesting point of our study is that we demonstrated that the cAMP/Epac/adhesion signaling module was ␤-cyclodextrin sensitive while the cAMP/PKA/proliferation one was not, strongly suggesting that both effects most likely rely on the existence of two ␤ 2 -AR populations localized in two distinct plasma membrane microdomains. The ␤ 2 -AR adhesion signaling platform would be concentrated in cholesterol-enriched domains while that mediating the ␤ 2 -AR-dependent antiproliferative effect would reside outside. These results are similar to those for the oxytocin receptor, another GPCR, for which promotion of cell growth inhibition would be taking place outside rafts/caveolin-rich domains (44) , while cell adhesion most likely requires specific ␤-integrin adhesion proteins concentrated in lipid raft domains in agreement with raft-regulating ␤-integrin activity (45) . In this context, one possible explanation for two different cAMP pathways engaged by ␤ 2 -AR activation could rely on the existence of two structurally different receptor conformations stabilized by the agonist, depending on its localization inside or outside cholesterol-enriched raft membrane domains. Consistent with this hypothesis, a recent study reported that cholesterol alters the structural properties of ␤ 2 -AR (46) and that this could in part influence ␤ 2 -AR ligand binding response. Moreover, the presence of two different pools of ␤ 2 -ARs, both inside and outside rafts in MCF-10A cells, is not aberrant since this receptor was already localized inside (47) or outside (48) lipid rafts, depending on the cell type. Numerous examples of GPCR localization determining signaling output are now available in the literature (40) and could easily reconcile the fact that ␤ 2 -ARs concentrated in lipid rafts control cell adhesion while the ␤ 2 -ARs localized in nonraft domains inhibit cell proliferation.
The second interesting observation in our study is the capacity of the ␤ 2 -AR to simultaneously couple to dual AC/cAMP signaling modules, 1 impacting on Epac activation and another on PKA, to regulate two individual signaling outcomes. Since both PKA and Epac, the two main cAMP effectors, are ubiquitously expressed in all cells, it is not surprising that increasing intracellular cAMP levels nonspecifically leads to the concomitant activation of both effectors. However, the existence of two highly coordinated cAMP effectors controlled by specific receptor activation argues for a spatiotemporal control of the cAMP signaling pathways initiated in a cell. Studies in this field have shown that GPCR activation can select one of the two cAMP effectors, thus favoring PKA or Epac activation depending on the cellular context (28, 49) . PKA and Epac can act antagonistically (50, 51) , but concomitant activation of both effectors by the same receptor has also been reported to synergize the regulation of a common downstream effector (52, 53) . To our knowledge, the identification of a single receptor mediating both Epac and PKA activation leading to different signaling outcomes has not been reported previously. Compartmentalized cAMP signaling within specific spatially sequestered receptor-AC-PKA/Epac-PDE modules in rafts and nonraft domains most probably accounted for this cAMP output diversity (54, 55) . In line with this as- sumption, ␤ 1 -AR, able to promote both PKA and Epac activation in adult cardiomyocytes, was shown to exist as two subpopulations localized in lipid rafts and nonraft domains, and only the ␤ 1 -AR localized inside rafts was able to elicit PKA activation (56) . Indeed, segregation of different and specific ␤ 2 -AR/cAMP signaling modules expressed in discrete parts of the plasma membrane could relate to a number of factors: coupling of ␤ 2 -AR with specific AC isoforms; localization of specific ACs in defined structural membrane domains; sequestration of Epac/PKA by specific A-kinase anchoring proteins (AKAPs; ref. 55 ; Ͼ70 different AKAP isoforms have been identified so far, ref. 57, and they have been shown to sequester highly diverse proteins, such as GPCRs, ACs, PDEs, PKAs, and Epac); and selective anchorage of PDEs, enzymes that degrade cAMP, to distinct intracellular sites (55) . It follows that the equilibrium between these different proteins could pattern the cAMP response as recently highlighted (58) . Until now, segregated cAMP signaling at the plasma membrane has been only depicted through the use of FRET-based biosensor imaging, allowing real-time and spatial resolution of cAMP local production in a single cell (59) . Thus, classical other approaches measuring total cAMP production with poor spatiotemporal resolution most probably miss cAMP production in discrete cell compartments. Accordingly, in our study, femtomolar activation of cAMP/Epac/adhesion signaling module by ISO could not be picked out from global cAMP measurements. Another intriguing finding of our study is the biphasic activation MCF-10A cells adhesion promoted by ISO, with both phases associated with cAMP/Epac signaling localized in cholesterolenriched domains. While our study did not dissect this phenomenon, several explanations could be inferred, such as the activation of 2 Epac isoforms (Epac1 and Epac2) by ␤ 2 -AR to coordinate cell adhesion, each of them potentially compartmentalized in different rafts domains (caveolae vs. noncaveolae rafts).
To our knowledge, little is known about ␤-adrenergic action in noncancer breast cells. Here we demonstrate that ␤ 2 -AR stimulation of MCF-10A cells promotes a rapid increase in cell adhesion and an additional inhibition of cell proliferation. This result is consistent with a previous report, describing that, in the same cells, ␤-AR stimulation promotes lumen formation in 3-dimensional cultures as a reflection of cell differentiation, a process known to require cell growth inhibition (5). Predominant ␤ 2 -AR subtype expression was also evidenced in mammary glands from different species (60, 61) . The cAMP-dependent inhibitory action of ␤ 2 -adrenergic agonists on cell proliferation observed in MCF-10A cells is consistent with previous in vitro and in vivo studies in different breast cancer cell lines. Pirbuterol (a ␤ 2 -AR agonist) inhibits the growth of human breast cancer cells in vivo by blocking the Raf-1/Erk1/2 pathway via a cAMP/PKAdependent mechanism (28) . ISO suppresses the growth of MDA-MB-231 human breast cancer cells through increased cAMP production, and this effect is blocked by propranolol and mimicked by 8-BrcAMP (21) . In addition, we have previously demonstrated that in several breast cancer cell lines, the activation of endogenous ␤ 2 -AR is associated with a decrease in cell proliferation. This effect is mimicked by cAMP analogs and is PKA dependent (23) .
In this study, we found exclusive actions for both PKA and Epac, since Epac was promoting cell adhesion while PKA was specifically controlling the inhibition of MCF-10A cell growth. Bos et al. (62) supported a model in which PKA can directly phosphorylate and inactivate Raf1, leading to Erk1/2 pathway inhibition. In contrast, and consistent with the Epac-independent Erk1/2 inhibition observed in our study, Epac usually mediates the activation of Rap1 and is not directly involved in the regulation of the Raf1/B-Raf-Erk pathway (62, 63) . Pharmacological manipulation of both Epac and PKA allowed us to determine the specific involvement of Epac in ␤ 2 -AR agonist-induced cell adhesion through a PKA-independent mechanism. Similar results were obtained in an ovarian cancer cell line, where ␤ 2 -adrenergic stimulation induced integrin-mediated cell adhesion to fibronectin via cAMP production and Epac and Rap1 activation (16) .
In sumary, the ␤ 2 -AR reveals an intricate mode of cAMP signaling to coordinate control of both cell adhesion and proliferation. During the last few years, control of cellular signaling through the existence of compartmentalized modules has emerged as a fundamental mechanism allowing spatiotemporal regulation. Now deciphering the molecular mechanisms that underlay the different signaling modules remains a challenge in order to provide specific targeting of the desired cell behavior. In this study we provide new insights into ␤ 2 -AR-cAMP-signaling pathways governing adhesion/proliferation of the nontumor human breast cell line MCF-10A, which in turn could have a major impact in the field of cancer. The signaling mechanisms involved in cell adhesion and proliferation in these cells are a matter of great interest because they are key processes deregulated during tumor progression.
